3 terminated, 1 active not recruiting, 1 unknown. 5 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Terminated 3, Active not recruiting 1, Unknown 1 |
| Phase 2 | 4 | Terminated 2, Active not recruiting 1, Unknown 1 |
Follow oregovomab: new trials by email Literature Review of oregovomab trials Research Report on oregovomab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer Oregovomab, Bevacizumab, Paclitaxel - Ovarian Cancer by FIGO Stage, Ovarian Cancer Stage III | Phase 1 / Phase 2 | Active not recruiting | CanariaBio Inc. | 54 | 2021-03-17 | 2026-04-06 |
| Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin Oregovomab, Nivolumab, Chemotherapy - Epithelial Ovarian Cancer | Phase 1 / Phase 2 | Unknown | National Cancer Centre, Singapore | 31 | 2020-10-07 | 2021-12-01 |
| The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer Oregovomab, Poly ICLC - Cancer of Ovary, Neoplasms, Ovarian | Phase 1 | Terminated | CanariaBio Inc. | 10 | 2017-05-30 | 2020-12-22 |
| Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin Nivolumab, Oregovomab - Epithelial Ovarian Cancer | Phase 1 / Phase 2 | Terminated | National Cancer Centre, Singapore | 13 | 2017-02-22 | 2022-06-13 |
| A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma oregovomab - Ovarian Neoplasms | Phase 1 / Phase 2 | Terminated | Unither Pharmaceuticals | 24 | 2002-03-01 | 2007-12-18 |
Carcinoma, Ovarian Epithelial (3) · Ovarian Neoplasms (3)
CanariaBio Inc. (2) · National Cancer Centre, Singapore (2) · Unither Pharmaceuticals (1)
Singapore (2) · United States (2) · South Korea (1)
Christopher Nicodemus, MD FACP (1) · Dr Jung KH, MD (1) · Jack Chan (1) · Jack Chan, MD (1)